Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

2 clusters · 20 sources · 8 days · First seen 9 days ago · Last updated 2 days ago

Categories: BUSINESS

Eli Lilly Q2 2026 earnings and revenue surge

Entities: Eli Lilly and Company · Excelsior Advisor Network LLC · China National Reimbursement Drug List · Tilray Brands · UGI Corporation

Overview

Eli Lilly’s shares rose modestly on July 28, 2026 after analysts lifted price targets ahead of its earnings release. The company posted Q2 2026 non‑GAAP earnings of $8.38 per share, well above the $6.07 consensus, and revenue of about $23 billion – a 48 % year‑over‑year increase driven by its obesity‑treatment portfolio. Sales of the diabetes drug Mounjaro jumped 91 % to $9.9 billion and the weight‑loss drug Zepbound grew 44 % to $4.9 billion, together accounting for roughly two‑thirds of quarterly revenue. Worldwide realized prices for the GLP‑1 medicines fell 13 % (3 % in the United States, 36 % outside) after Mounjaro entered China’s national reimbursement list. Adjusted net income rose 32 % to $7.5 billion, prompting Lilly to raise its full‑year 2026 revenue outlook to $85‑$87 billion and reaffirm its EPS target. In the same quarter Lilly launched an oral obesity pill, Foundayo, which generated $98 million in sales, short of the $105.6 million analysts had expected.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 7 SOURCES] Eli Lilly's second‑quarter 2026 revenue was $23 billion, up 48 percent year over year. (8a7e82cf-8011-462b-b032-926cb4472009, 297f2b36-2629-492d-8bd1-de37ff6ee2f5, b226bd11-a2fb-4905-b247-1e4a4d532339, e56b28)
[● 7 SOURCES] Mounjaro sales were $9.9 billion, up 91 percent year over year. (multiple)
[● 7 SOURCES] Zepbound sales were $4.9 billion, up 44 percent year over year. (multiple)
[● 7 SOURCES] Obesity drugs accounted for about two‑thirds of Eli Lilly's quarterly revenue. (multiple)
[● 6 SOURCES] Eli Lilly raised its full‑year 2026 revenue forecast to $85‑87 billion. (multiple)

Timeline

2 days ago

[BUSINESS] 18 sources
Eli Lilly Q2 Revenue Jumps 48% on Obesity Drug Sales
Eli Lilly’s Q2 revenue hit $23 billion, up 48%, led by Mounjaro ($9.9 bn) and Zepbound ($4.9 bn); obesity drugs now make up about two‑thirds of sales, prices fell 13% globally, and the full‑year outlook was nud
9 days ago

[BUSINESS] 4 sources
Eli Lilly shares rise 2.1% on analyst upgrades; MercadoLibre to report Q2 2026 earnings; Elicio Therapeutics forecasts a
Eli Lilly shares rose 2.1% as analysts lifted price targets; MercadoLibre will release Q2 2026 results on Aug 5; Elicio Therapeutics forecasts a Q2 2026 loss of $0.53 per share.

Sources

aijourn.com · bygumbygolly.com · elceo.com · finbold.com · gazeta.eu · heartofdublin.com · lesaffaires.com · lesinguliersete.fr · levisonenterprises.com · lopinion.fr · mommygearest.com · moneytimes.com.br · news.alphastreet.com · otravel.com · pharmexec.com · seekingalpha.com · seucreditodigital.com.br · shippingherald.com · stocknews.com · valor.globo.com

This summary has been updated 5 times: see revision history